Summit X, LLC Abb Vie Inc. Transaction History

Summit X, LLC

$423 Million
Q3 2024

A detailed history of Summit X, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Summit X, LLC holds 17,836 shares of ABBV stock, worth $3.03 Million. This represents 0.83% of its overall portfolio holdings.

Number of Shares

17,836

Previous 17,507 1.88%

Holding current value

$3.03 Million

Previous $3 Million 17.32%

% of portfolio

0.83%

Previous 0.69%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$163.84 - $199.33 $53,903 - $65,579	329 Added 1.88%	17,836 $3.52 Million
Q2 2024 Aug 13, 2024	BUY	$154.79 - $180.76 $45,043 - $52,601	291 Added 1.69%	17,507 $3 Million
Q1 2024 May 08, 2024	BUY	$159.82 - $182.1 $27,489 - $31,321	172 Added 1.01%	17,216 $3.14 Million
Q4 2023 Feb 08, 2024	SELL	$137.6 - $154.97 $35,363 - $39,827	-257 Reduced 1.49%	17,044 $2.64 Million
Q3 2023 Nov 03, 2023	SELL	$133.59 - $154.65 $358,421 - $414,925	-2,683 Reduced 13.43%	17,301 $2.58 Million
Q2 2023 Aug 09, 2023	SELL	$132.51 - $164.9 $104,947 - $130,600	-792 Reduced 3.81%	19,984 $2.69 Million
Q1 2023 May 10, 2023	SELL	$144.61 - $166.54 $142,296 - $163,875	-984 Reduced 4.52%	20,776 $3.31 Million
Q4 2022 Feb 02, 2023	BUY	$138.31 - $165.87 $171,919 - $206,176	1,243 Added 6.06%	21,760 $3.52 Million
Q3 2022 Nov 01, 2022	SELL	$134.21 - $153.93 $168,567 - $193,336	-1,256 Reduced 5.77%	20,517 $2.78 Million
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $24,496 - $31,142	-178 Reduced 0.81%	21,773 $3.33 Million
Q1 2022 May 05, 2022	BUY	$131.98 - $163.75 $17,949 - $22,270	136 Added 0.62%	21,951 $3.56 Million
Q4 2021 Jan 19, 2022	BUY	$107.43 - $135.93 $92,819 - $117,443	864 Added 4.12%	21,815 $2.96 Million
Q3 2021 Oct 19, 2021	BUY	$106.4 - $120.78 $64,797 - $73,555	609 Added 2.99%	20,951 $2.27 Million
Q2 2021 Jul 16, 2021	BUY	$105.21 - $117.21 $38,086 - $42,430	362 Added 1.81%	20,342 $2.29 Million
Q1 2021 May 10, 2021	SELL	$102.3 - $112.62 $27,825 - $30,632	-272 Reduced 1.34%	19,980 $2.17 Million
Q4 2020 Jan 29, 2021	SELL	$80.49 - $108.67 $874,201 - $1.18 Million	-10,861 Reduced 34.91%	20,252 $2.17 Million
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $42,783 - $50,213	498 Added 1.63%	31,113 $26.1 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $73,663 - $98,572	1,004 Added 3.39%	30,615 $3.01 Million
Q1 2020 May 13, 2020	SELL	$64.5 - $97.79 $980,142 - $1.49 Million	-15,196 Reduced 33.91%	29,611 $2.25 Million
Q4 2019 Jan 23, 2020	SELL	$72.13 - $90.25 $611,229 - $764,778	-8,474 Reduced 15.9%	44,807 $3.96 Million
Q3 2019 Oct 15, 2019	SELL	$62.98 - $75.72 $280,890 - $337,711	-4,460 Reduced 7.72%	53,281 $4.04 Million
Q2 2019 Aug 13, 2019	BUY	$65.7 - $83.98 $1.9 Million - $2.43 Million	28,933 Added 100.43%	57,741 $4.2 Million
Q1 2019 May 13, 2019	BUY	$77.14 - $90.79 $1.96 Million - $2.31 Million	25,422 Added 750.8%	28,808 $2.33 Million
Q4 2018 Feb 13, 2019	BUY	$77.85 - $96.01 $92,330 - $113,867	1,186 Added 53.91%	3,386 $313,000
Q3 2018 Nov 01, 2018	BUY	$88.91 - $98.84 $355 - $395	4 Added 0.18%	2,200 $208,000
Q2 2018 Sep 24, 2018	BUY	$89.78 - $106.23 $122,011 - $144,366	1,359 Added 162.37%	2,196 $203,000
Q2 2018 Aug 13, 2018	SELL	$89.78 - $106.23 $121,741 - $144,047	-1,356 Reduced 61.83%	837 $203,000
Q1 2018 May 23, 2018	SELL	$92.01 - $123.21 $27,418 - $36,716	-298 Reduced 11.96%	2,193 $207,000
Q4 2017 Jan 23, 2018	BUY	$89.56 - $98.21 $268 - $294	3 Added 0.12%	2,491 $241,000
Q3 2017 Oct 17, 2017	BUY	$69.85 - $89.22 $173,786 - $221,979	2,488	2,488 $222,000

Others Institutions Holding ABBV

# of Institutions

3,837

Shares Held

1.25B

Call Options Held

15.7M

Put Options Held

11.3M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $300B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit X, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit X, LLC with notifications on news.

Account